Early detection of lung cancer by using an autoantibody panel in Chinese population
Shengxiang Ren(Tongji University), Fred R. Hirsch(Tisch Hospital), Xuejun Hu(Zoucheng People's Hospital), Yayi He(Helix (United States)), Jun Zhang(OSF HealthCare), Yan Li(The University of Texas Southwestern Medical Center), Xiaohong Xu(Zhejiang Cancer Hospital), Tao Jiang(Tongji University), Shucai Zhang(Northeastern University), Jing Zhou(Tianjin Medical University Cancer Institute and Hospital), Hourong Cai(Boehringer Ingelheim (United States)), Weijing Cai(Hebei Medical University), Xiaopeng Liu(Hangzhou Cancer Hospital), Hui Yu(Jiangnan University), Zhiyong Ma(Zhengzhou University), Caicun Zhou(Tongji University)
Cited by 203
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k